Medical Devices in Thoughts from the Centre
- Select a blog category
By Mark Steedman, PhD, Research Manager, Centre for Health Solutions
“Alexa… Volume up!”
Like many children his age, my four-year old nephew loves the Frozen soundtrack, and he recently figured out how to turn up the volume from anywhere in the room without having to be close to the speaker. He uses the voice assistant that’s always on and always listening.
By Karen Taylor, Director, Centre for Health Solutions
Last week we provided an update on the three health care predictions from our November 2017 report - The future awakens: Life Sciences and health care predictions 2022. As promised, this week’s blog reviews developments during 2018 on the three predictions that are more life sciences focused and what we might expect to see in 2019.
My Take: Highlights from the 2018 FT Conference panel discussion on the potential for a successful life sciences economy in the UK
By John Haughey, Deloitte Industry Leader, Life Sciences & Health Care
Earlier this month I had the pleasure of chairing a panel of life science experts at the Global Financial Times Pharmaceutical and Biotechnology conference.1 The conference brought together some of our industry’s leading minds to discuss the commercial conundrums of disease prevention, the transformational impact of advanced gene and cell therapies and the hope and hype of patient-centricity. The discussion topic for my panel was - ‘Big Bang? Industrial Strategy - Creating a Successful Life Sciences Economy’, and was focused on the UK’s Industrial Strategy and in particular the UK’s sector deal for life sciences.2 In this week’s blog I wanted to share some of my key takeaways from our animated and insightful discussion.
By Karen Taylor, Director, Centre for Health Solutions
Following our 2014 and 2017 Life Science and Health Care Predictions reports, ‘A bold future?’ and ‘The future awakens’, this week we launched our third predictions report, A bold future for Life Sciences Regulation: Predictions 2025. This year’s report presents an unashamedly optimistic view on what Life Sciences regulation might look like in 2025 if both life science companies and regulators were to work more collaboratively, embrace disruptive technologies, and acquire new skills and talent. We argue that this would improve not only the productivity of the regulators and industry but also provide patients with access to the latest medical innovation much sooner. We also imagine through a series of ‘portraits’ how a regulator, company and patient might behave in 2025. This week’s blog provides an overview of the four predictions presented in our future of regulation report and examples of the evidence today that enable us to predict a bold future for life sciences regulation in 2025.
Consumers want connected medical devices, but demand for digital experts could put further strain on the talent pool for medtech
By Pedro Arboleda, managing director, Deloitte Consulting LLP
This week, running from September the 24th to the 26th, our colleagues in the US attended AdvaMed’s annual MedTech Conference. At the conference participants heard about the latest innovations, such as new digital products that incorporate the latest advances in wireless technology and increasingly powerful computing capabilities for generating clinical and economic insights. This week’s blog, by Pedro Arboleda, first appeared on the US Center for health solutions website.1 Below, he discusses his worry that given the rapid advancement in digital technologies the industry might overlook another important change that is occurring in parallel—the ability to attract the specific digital talent needed to deliver on the promise of connected medical devices.
by Greg Reh, vice chairman, US and Global Life Sciences leader, Deloitte Consulting LLP
In July 2018, we released our report, Medtech and The Internet of Medical Things, which examined the proliferation of medical grade Internet of Things (IoT) technologies, the benefits they provide, the challenges that need to be overcome for them to become a staple in health care delivery and what the future of the medtech industry may look like. This week’s blog, by Deloitte’s global Life Sciences leader Greg Reh, first appeared on the US Center for Health Solutions blog site.1 The blog presents his take on some of the findings from the report, and the challenges and opportunities for Medtech in this rapidly evolving space.
Medtech and the Internet of Medical Things: How connected medical devices are transforming health care
by Dr. Mark Steedman, Research Manager, Centre for Health Solutions
This week, we launched our report Medtech and the Internet of Medical Things: How connected medical devices are transforming health care. Our report takes an in-depth look at how connectivity is impacting the medtech industry, the challenges and opportunities that medtech companies are facing due to the rise of the Internet of Medical Things (IoMT), the specific role connected medical devices are playing in the growth of the IoMT and what the future will bring for medtech and the IoMT.
by Karen Taylor, Director, Centre for Health Solutions
In November 2017 we launched our report - ‘The future awakens: life sciences and health care predictions 2022’ - which provides an overview of six predictions that we believe will transform health care. This article, which first appeared in the Med Tech Innovation (MIT) news magazine,1 discusses the key medical technology innovations that I believe will impact health care in 2018.
This week’s blog appeared as an article in Deloitte Insights in the CIO Journal from The Wall Street Journal last month and is written by our colleagues in the US: Veronica Lim, Principle; Russell Jones, partner; and Nick Sikorski, senior consultant. The article, linked to a Dbrief Webcast in May 2017 titled Medical devices and the Internet of Things: A three-layer defence against cyber threats, discusses the cyber security issues affecting new and legacy medical devices and the strategies companies can use to mitigate the risks associated with them.
This week we’re delighted to feature a ‘my take’ written by our US colleague Harry Greenspun – MD, Director, Center for Health Solutions. We thought it would strike a cord with those fair weather cyclists who are starting to emerge from winter hibernation, but also to those of us interested in learning how the US Med-Tech industry is adapting to new value based payment models.